Published in Obesity and Diabetes Week, June 27th, 2005
MacroPore will use these funds primarily to support the research and development of its regenerative cell technology.
MacroPore Biosurgery specializes in the discovery and development of regenerative medicine therapies. The company has 2 principal technology platforms, adipose-derived regenerative cells and bioresorbable implants.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.